Join the Pneumonia group to help and get support from people like you.
Pneumonia News (Page 2)
Related terms: Bronchopneumonia, Community-acquired pneumonia, Acute Pneumonia
Olympic Legend Mary Lou Retton Battling Rare Form of Pneumonia
WEDNESDAY, Oct. 11, 2023 – Olympic icon Mary Lou Retton – the first American woman to win the all-around gold medal in women's gymnastics – is in intensive care with a rare type of pneumonia and...
Routine Vaccines Can Cut Risk for Later Alzheimer Disease
WEDNESDAY, Aug. 23, 2023 – Prior vaccinations against tetanus and diphtheria, shingles, and pneumococcus are all associated with a reduced risk for developing Alzheimer disease, according to a study...
Studies Explore Risks for Exposure to Antenatal Corticosteroids
WEDNESDAY, Aug. 9, 2023 – Exposure to antenatal corticosteroids is associated with serious infection in children and with increased short- and long-term adverse health outcomes, according to two...
New Report Measures Scope of Damage From Medical Mistakes
THURSDAY, July 20, 2023 – About 795,000 Americans die or are permanently disabled every year due to misdiagnosed medical conditions. A new analysis led by experts at Johns Hopkins Medicine in...
Paratek Pharmaceuticals Announces FDA Approval of Nuzyra (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
BOSTON, June 01, 2021 (GLOBE NEWSWIRE) – Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
FDA Approves Fetroja (cefiderocol) for the Treatment of Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
OSAKA, Japan & FLORHAM PARK, N.J.--(BUSINESS WIRE) September 28, 2020 --Shionogi & Co., Ltd. (hereafter “Shionogi”) today announces that the U.S. Food and Drug Administration (FDA) has approved a sup...
FDA Approves Merck’s Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
KENILWORTH, N.J.--(BUSINESS WIRE) June 5, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved a...
FDA Approves Baxdela (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
MORRISTOWN, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) – Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
FDA Approves Xenleta (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)
DUBLIN, Ireland, Aug. 19, 2019 (GLOBE NEWSWIRE) – Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
FDA Approves Nuzyra (omadacycline) for Community-Acquired Bacterial Pneumonia and Acute Skin and Skin Structure Infections
BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) – Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced that the U.S. Food and Drug Administration (FDA) has approved Nuzyra (omadacycline) for the...
FDA Approves Avycaz (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
DUBLIN, Feb. 1, 2018 /PRNewswire/ – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Allergan's...
FDA Medwatch Alert: Fluoroquinolone Antibacterial Drugs for Systemic Use: Drug Safety Communication - Warnings Updated Due to Disabling Side Effects
ISSUE: FDA approved changes to the labels of fluoroquinolone antibacterial drugs for systemic use (i.e., taken by mouth or by injection). Includes the following currently available fluoroquinolones:...
Allergan Receives FDA Approval of Teflaro (ceftaroline fosamil) for Pediatric Patients
DUBLIN, May 31, 2016 /PRNewswire/ – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved the company's...
Theravance Biopharma Announces FDA Approval of Expanded Label for Vibativ (telavancin)
DUBLIN, IRELAND – (Marketwired) – 05/09/16 – Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that the U.S. Food and Drug Administration (FDA)...
FDA Approves Vibativ for Hospitalized Patients with Bacterial Pneumonia
June 21, 2013 – The U.S. Food and Drug Administration today expanded the approved use of the antibiotic Vibativ (telavancin) to treat patients with hospital-acquired and ventilator-associated...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related drug support groups
amoxicillin, metronidazole, doxycycline, clindamycin, azithromycin, Bactrim, Cipro, Zithromax, ciprofloxacin, view more... Flagyl, Levaquin, Augmentin, erythromycin, levofloxacin, clarithromycin, sulfamethoxazole / trimethoprim, vancomycin, amoxicillin / clavulanate, cefdinir, Bactrim DS, tetracycline, Rocephin